Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

3.65
+0.08002.24%
Post-market: 3.710.0601+1.65%19:48 EDT
Volume:1.34M
Turnover:4.94M
Market Cap:328.21M
PE:-1.28
High:3.77
Open:3.70
Low:3.58
Close:3.57
52wk High:4.54
52wk Low:0.9101
Shares:89.92M
Float Shares:89.58M
Volume Ratio:0.46
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8488
EPS(LYR):-2.8795
ROE:-188.58%
ROA:-33.76%
PB:17.10
PE(LYR):-1.27

Loading ...

Editas Medicine Q2 EPS $(0.63) Misses $(0.38) Estimate, Sales $3.578M Beat $1.666M Estimate

Benzinga
·
Aug 13

Editas Medicine's CD19 HD Allo CAR T Program Receives IND/CTA Acceptance, Secures Milestone Payment Through Collaboration with Bristol Myers Squibb

Reuters
·
Aug 13

Editas Medicine Inc. to Present Preclinical Data at ASGCT Annual Meeting

Reuters
·
Aug 13

BRIEF-Editas Medicine Q2 Net Income USD -53.235 Million Vs. IBES Estimate USD -33.4 Million

Reuters
·
Aug 13

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

THOMSON REUTERS
·
Aug 13

Editas Medicine Q2 EPS USD -0.63

THOMSON REUTERS
·
Aug 13

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Address Challenges in Gene Therapy and Expand Market Reach

Reuters
·
Aug 12

Editas Medicine Inc. CFO Amy Parison Reports Disposal of Common Shares

Reuters
·
Aug 09

Editas Medicine Inc.'s EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Reuters
·
Aug 05

Editas Medicine Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Aug 01

Editas Medicine Announces Breakthrough in In Vivo Gene Editing for Sickle Cell Disease and Beta Thalassemia at European Hematology Association 2025 Congress

Reuters
·
Jun 12

Editas Medicine Inc. EVP and Chief Scientific Officer Linda Burkly Reports Disposal of Common Shares

Reuters
·
Jun 05

Editas Medicine CEO Neil O'Neill Reports Disposal of Common Shares

Reuters
·
Jun 05

Editas Medicine Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 03

Editas Medicine Inc. Unveils Innovative Gene Editing Strategies to Transform Therapeutics Globally

Reuters
·
May 29

BRIEF-Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting

Reuters
·
May 14

Editas Medicine Announces Promising Preclinical Results for In Vivo Gene Editing Approach to Treat Sickle Cell Disease and Beta Thalassemia

Reuters
·
May 14

Editas Medicine Is Maintained at Outperform by Baird

Dow Jones
·
May 13

Editas Medicine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

Benzinga
·
May 13